Lombard Medical Announces First Commercial Altura® Endovascular Stent Graft Procedure in Germany Following LINC

IRVINE, Calif., Feb. 24, 2016 -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the first commercial procedure in Germany using the revolutionary new Altura® Endovascular Stent Graft was successfully completed at the Saarland University Medical Center-Clinic for Diagnostic and Interventional Radiology following the late January Leipzig Interventional Course (LINC) in Leipzig, Germany.  The hospital is a major EVAR center in the state of Saarland, Germany.

“We are honored to be the first German center to complete an Altura EVAR procedure following last month’s LINC meeting and have additional cases scheduled in the coming weeks,” said Dr. Alexander Massmann, Saarland University Medical Center.  “We found the new Altura stent graft from Lombard easy to use, with a minimal amount of steps required to implant the stent graft.  We were especially impressed with the 14F ultra low profile design and the elimination of the gate cannulation step which can be a real procedural time saver.”

“We have been pleased with the interest and uptake of our new Altura stent graft following a successful LINC meeting in January,” said Lombard CEO Simon Hubbert.  “We are already receiving positive feedback from physicians in the UK and Germany regarding the unique features of Altura that deliver a simplified, more accurate and faster EVAR procedure than currently available stent grafts treating mainstream AAA anatomy.  We’d like to thank Dr. Massmann and Univ. Prof. Dr. Arno Bücker M.Sc., for this opportunity.”

About Lombard Medical, Inc.

Lombard Medical, Inc. is an Irvine, CA-based medical device company focused on the $1.7bn market for minimally invasive treatment of abdominal aortic aneurysms (AAAs).  The Company has global regulatory approval for Aorfix™, an endovascular stent graft which has been specifically designed to treat patients with the broadest range of AAA anatomies, including aortic neck angulation up to 90 degrees.  The Company has also achieved CE Mark for the Altura™ endograft system, an innovative ultra-low profile endovascular stent graft that offers a simple and predictable solution for the treatment of more standard AAA anatomies.  Altura was launched in Europe in January 2016, with an international rollout planned for later in 2016.  For more information, please visit www.lombardmedical.com. 

Forward-Looking Statements

This announcement contains forward-looking statements that reflect the Company’s current expectations regarding future events.  These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “expect,” “future,” “anticipate,” “look forward to,” “intend,” “plan,” “foresee,” “may,” “should,” “will,” “estimates,” “outlook,” “potential,” “optimistic,” “confidence,” “continue,” “evolve,” “expand,” “growth” or words and phrases of similar meaning. Statements that describe objectives, plans or goals also are forward-looking statements.  Forward-looking statements are subject to risks, management assumptions and uncertainties.  Actual results could differ materially from those projected herein and depend on a number of factors, including the success of the Company’s research and development and commercialization strategies, the uncertainties related to the regulatory process and the acceptance of the Company’s products by hospitals and other medical professionals, the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company’s products and increased volatility in foreign exchange rates, the inability to raise additional funds, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s Form 20-F filed with the Securities and Exchange Commission dated April 29, 2015.  Readers are urged to consider these factors carefully in evaluating the forward-looking statements. The forward-looking statements included herein are made only as of the date of this report and the Company undertakes no obligation to update these statements in the future.

For further information:
Lombard Medical, Inc. 
Simon Hubbert, Chief Executive Officer
Tel: 949 379 3750 / +44(0)1235 750 800
William J. Kullback, Chief Financial Officer
Tel: 949 748 6764